Competition for patients with hepatitis C virus (HCV) genotype 1 infections, the most common in the U.S. is heating up. In addition to Harvoni (ledipasvir and sofosbuvir, Gilead Sciences Inc.) and Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir, Abbvie Inc.), Merck & Co. Inc. gained FDA approval of its once-daily treatment, Zepatier (elbasvir and grazoprevir), earlier this year. Read More
We live in an aging world, according to a U.S. Census Bureau report of the same name issued last month. Based on 2015 data, researchers Wan He and Daniel Goodkind of the Census Bureau and Paul Kowal of the World Health Organization's Study on Global Aging and Adult Health amassed some startling statistics. Read More
